{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T16:02:00Z","timestamp":1753891320100,"version":"3.41.2"},"reference-count":31,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,5,9]],"date-time":"2025-05-09T00:00:00Z","timestamp":1746748800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:p>Type I melanoma antigen gene proteins CT7 (<jats:italic>MAGE-C1\/CT7<\/jats:italic>), a cancer-testis (CT) gene, correlated with clinical parameters at diagnosis of multiple myeloma (MM). We first analyzed single-cell ribonucleic acid sequencing data from public databases to evaluate the expression of <jats:italic>MAGE-C1\/CT7<\/jats:italic> in MM patients and showed that <jats:italic>MAGE-C1\/CT7<\/jats:italic> is highly and specifically expressed in the MM cells. We then interrogated data from 216 consecutive cases with <jats:italic>MAGE-C1\/CT7<\/jats:italic> transcripts by quantitative real-time polymerase chain reaction longitudinally monitored in our center. The positive rate of <jats:italic>MAGE-C1\/CT7<\/jats:italic> at baseline was 87.3%, with a median level of 4.46% (0.01\u2013939.5). In univariate Cox regression analysis, peri-ASCT <jats:italic>MAGE-C1\/CT7<\/jats:italic> status showed better discriminatory ability in PFS and survival than peri-ASCT multi-parameter flow-cytometry status assessed by flow cytometry. In multivariate analysis, patients who were <jats:italic>MAGE-C1\/CT7-<\/jats:italic>negative pre-transplant and posttransplant had significantly better PFS than those who were positive in both determinations (HR\u202f=\u202f0.33, 95% CI: 0.14, 0.80, <jats:italic>p<\/jats:italic>\u202f=\u202f0.01). In 69 patients with informative samples, we found a 2-log decrease in <jats:italic>MAGE-C1\/CT7<\/jats:italic> transcript concentration after the second induction cycle correlated with achieving negative <jats:italic>MAGE-C1\/CT7<\/jats:italic>-test results both pre-transplant and posttransplant (OR\u202f=\u202f6.08, 95% CI: 1.78, 20.74, <jats:italic>p<\/jats:italic>\u202f=\u202f0.004). Our data showed the predictive value of peri-ASCT frontline treatment. A 2-log decrease of <jats:italic>MAGE-C1\/CT7<\/jats:italic> post-induction cycle 2 compared to baseline correlated with a negative peri-ASCT <jats:italic>MAGE-C1\/CT7<\/jats:italic> status, providing an earlier prognostic marker of treatment response.<\/jats:p>","DOI":"10.3389\/fmed.2025.1566265","type":"journal-article","created":{"date-parts":[[2025,5,9]],"date-time":"2025-05-09T05:34:56Z","timestamp":1746768896000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Prognostic impact of dynamic changes of type I melanoma antigen gene proteins CT7 (MAGE-C1\/CT7) transcripts in multiple myeloma"],"prefix":"10.3389","volume":"12","author":[{"given":"Xuelin","family":"Dou","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fengrong","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yao","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lei","family":"Wen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guorui","family":"Ruan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaosu","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaojun","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert Peter","family":"Gale","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jin","family":"Lu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2025,5,9]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1038\/s41408-019-0205-9","article-title":"Current status of autologous stem cell transplantation for multiple myeloma","volume":"9","author":"Al Hamed","year":"2019","journal-title":"Blood Cancer J"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1038\/s41408-020-00359-2","article-title":"Multiple myeloma current treatment algorithms","volume":"10","author":"Rajkumar","year":"2020","journal-title":"Blood Cancer J"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"1507","DOI":"10.1182\/blood-2017-05-743203","article-title":"How I treat myeloma with new agents","volume":"130","author":"Moreau","year":"2017","journal-title":"Blood"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"5988","DOI":"10.1182\/bloodadvances.2020002827","article-title":"A large meta-analysis establishes the role of Mrd negativity in long-term survival outcomes in patients with multiple myeloma","volume":"4","author":"Munshi","year":"2020","journal-title":"Blood Adv"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"1343","DOI":"10.1158\/1078-0432.CCR-08-0989","article-title":"Longitudinal analysis and prognostic effect of cancer-testis antigen expression in multiple myeloma","volume":"15","author":"Atanackovic","year":"2009","journal-title":"Clin Cancer Res"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1182\/blood-2004-12-4931","article-title":"The cancer-testis antigens Ct7 (Mage-C1) and Mage-A3\/6 are commonly expressed in multiple myeloma and correlate with plasma-cell proliferation","volume":"106","author":"Jungbluth","year":"2005","journal-title":"Blood"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"785","DOI":"10.3324\/haematol.2009.014464","article-title":"Cancer-testis antigens Mage-C1\/Ct7 and Mage-A3 promote the survival of multiple myeloma cells","volume":"95","author":"Atanackovic","year":"2010","journal-title":"Haematologica"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"2863","DOI":"10.1200\/JCO.2015.61.2267","article-title":"Revised international staging system for multiple myeloma: a report from international myeloma working group","volume":"33","author":"Palumbo","year":"2015","journal-title":"J Clin Oncol"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"e538","DOI":"10.1016\/S1470-2045(14)70442-5","article-title":"International myeloma working group updated criteria for the diagnosis of multiple myeloma","volume":"15","author":"Rajkumar","year":"2014","journal-title":"Lancet Oncol"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1046\/j.1365-2141.2003.04355.x","article-title":"Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the international myeloma working group","volume":"121","year":"2003","journal-title":"Br J Haematol"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"e328","DOI":"10.1016\/S1470-2045(16)30206-6","article-title":"International myeloma working group consensus criteria for response and minimal residual disease assessment in multiple myeloma","volume":"17","author":"Kumar","year":"2016","journal-title":"Lancet Oncol"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1016\/j.clml.2022.01.013","article-title":"The importance of Fish signal cut-off value and copy number variation for 1q21 in newly diagnosed multiple myeloma: is it underestimated?","volume":"22","author":"Gao","year":"2022","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1186\/1476-4598-13-25","article-title":"The clinical value of the quantitative detection of four cancer-testis antigen genes in multiple myeloma","volume":"13","author":"Zhang","year":"2014","journal-title":"Mol Cancer"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"1888","DOI":"10.1016\/j.cell.2019.05.031","article-title":"Comprehensive integration of single-cell data","volume":"177","author":"Stuart","year":"2019","journal-title":"Cell"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"5381","DOI":"10.1002\/sim.5958","article-title":"Estimating and comparing time-dependent areas under receiver operating characteristic curves for censored event times with competing risks","volume":"32","author":"Blanche","year":"2013","journal-title":"Stat Med"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.3390\/cells12060926","article-title":"Biology of Cancer-testis antigens and their therapeutic implications in Cancer","volume":"12","author":"Nin","year":"2023","journal-title":"Cells"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2012\/257695","article-title":"Cancer\/testis antigen Mage-C1\/Ct7: new target for multiple myeloma therapy","volume":"2012","author":"De Carvalho","year":"2012","journal-title":"Clin Dev Immunol"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1007\/s00262-012-1376-4","article-title":"Mage-C1\/Ct7 and Mage-C2\/Ct10 are frequently expressed in multiple myeloma and can be explored in combined immunotherapy for this malignancy","volume":"62","author":"de Carvalho","year":"2013","journal-title":"Cancer Immunol Immunother"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"156","DOI":"10.5045\/br.2021.2020335","article-title":"The expression of multiple cancer\/testis antigens can potentially be used to detect circulating disease and clonal evolution in the peripheral blood of multiple myeloma patients","volume":"56","author":"Shires","year":"2021","journal-title":"Blood Res"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"2383","DOI":"10.1007\/s00432-016-2231-3","article-title":"Cancer testis antigen Mage C1 can be used to monitor levels of circulating malignant stem cells in the peripheral blood of multiple myeloma patients","volume":"142","author":"Shires","year":"2016","journal-title":"J Cancer Res Clin Oncol"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"e27707","DOI":"10.1371\/journal.pone.0027707","article-title":"Targeting Mage-C1\/Ct7 expression increases cell sensitivity to the proteasome inhibitor bortezomib in multiple myeloma cell lines","volume":"6","author":"de Carvalho","year":"2011","journal-title":"PLoS One"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1080\/10428194.2016.1187271","article-title":"Expression of Mage-C1\/Ct7 provides prognostic information in multiple myeloma","volume":"58","author":"Xu","year":"2017","journal-title":"Leuk Lymphoma"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1182\/blood-2006-04-014480","article-title":"Cancer-testis antigens are commonly expressed in multiple myeloma and induce systemic immunity following allogeneic stem cell transplantation","volume":"109","author":"Atanackovic","year":"2007","journal-title":"Blood"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"2456","DOI":"10.1182\/blood-2018-06-858613","article-title":"Minimal residual disease negativity using deep sequencing is a major prognostic factor in multiple myeloma","volume":"132","author":"Perrot","year":"2018","journal-title":"Blood"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"2900","DOI":"10.1200\/JCO.2016.69.2517","article-title":"Depth of response in multiple myeloma: a pooled analysis of three Pethema\/gem clinical trials","volume":"35","author":"Lahuerta","year":"2017","journal-title":"J Clin Oncol"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1007\/s11899-021-00633-5","article-title":"Mrd assessment in multiple myeloma: Progress and challenges [J]","volume":"16","author":"Bertamini","year":"2021","journal-title":"Curr Hematol Malig Rep"},{"key":"ref27","first-page":"17","article-title":"Best practices for the assessment of measurable residual disease (Mrd) in multiple myeloma: further observations [J]","volume":"18","author":"Costa","year":"2020","journal-title":"Clin Adv Hematol Oncol"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"2423","DOI":"10.1182\/blood.2022016170","article-title":"Mrd in multiple myeloma: does Cr really matter?","volume":"140","author":"Paiva","year":"2022","journal-title":"Blood"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"3406","DOI":"10.1200\/JCO.21.02614","article-title":"Second revision of the international staging system (R2-Iss) for overall survival in multiple myeloma: a European myeloma network (Emn) report within the harmony project","volume":"40","author":"D'agostino","year":"2022","journal-title":"J Clin Oncol"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"e17","DOI":"10.1111\/bjh.18536","article-title":"The second revision of the international staging system (R2-Iss) stratifies progression-free and overall survival in multiple myeloma: real world data results in an Australian and New Zealand population [J]","volume":"200","author":"Tan","year":"2023","journal-title":"Br J Haematol"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"7255","DOI":"10.1182\/blood-2022-158751","article-title":"Is the second revision of the international staging system (R2-Iss) for multiple myeloma valid in a real-world population from China?","volume":"140","author":"Yan","year":"2022","journal-title":"Blood"}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2025.1566265\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,9]],"date-time":"2025-05-09T05:34:57Z","timestamp":1746768897000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2025.1566265\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,9]]},"references-count":31,"alternative-id":["10.3389\/fmed.2025.1566265"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2025.1566265","relation":{},"ISSN":["2296-858X"],"issn-type":[{"type":"electronic","value":"2296-858X"}],"subject":[],"published":{"date-parts":[[2025,5,9]]},"article-number":"1566265"}}